JP2014506787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506787A5 JP2014506787A5 JP2013552609A JP2013552609A JP2014506787A5 JP 2014506787 A5 JP2014506787 A5 JP 2014506787A5 JP 2013552609 A JP2013552609 A JP 2013552609A JP 2013552609 A JP2013552609 A JP 2013552609A JP 2014506787 A5 JP2014506787 A5 JP 2014506787A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- gne
- expression construct
- subject
- acid expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 102100033341 N-acetylmannosamine kinase Human genes 0.000 claims description 12
- 101000997654 Homo sapiens N-acetylmannosamine kinase Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 210000003414 extremity Anatomy 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 206010015866 Extravasation Diseases 0.000 claims description 2
- 230000036251 extravasation Effects 0.000 claims description 2
- 210000003127 knee Anatomy 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 2
- 101710179749 N-acetylmannosamine kinase Proteins 0.000 claims 2
- 238000002716 delivery method Methods 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101710178100 Probable UDP-N-acetylglucosamine 2-epimerase Proteins 0.000 claims 1
- 101710086464 Putative UDP-N-acetylglucosamine 2-epimerase Proteins 0.000 claims 1
- 241000282849 Ruminantia Species 0.000 claims 1
- 101710091363 UDP-N-acetylglucosamine 2-epimerase Proteins 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001840 diploid cell Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 description 2
- 108010060910 UDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinase Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438585P | 2011-02-01 | 2011-02-01 | |
| US61/438,585 | 2011-02-01 | ||
| PCT/US2012/023536 WO2012106465A2 (en) | 2011-02-01 | 2012-02-01 | Methods and compositions for increasing sialic acid production and treating sialic related disease conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017092571A Division JP2017158577A (ja) | 2011-02-01 | 2017-05-08 | シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014506787A JP2014506787A (ja) | 2014-03-20 |
| JP2014506787A5 true JP2014506787A5 (enExample) | 2016-07-28 |
Family
ID=46603295
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552609A Pending JP2014506787A (ja) | 2011-02-01 | 2012-02-01 | シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 |
| JP2017092571A Pending JP2017158577A (ja) | 2011-02-01 | 2017-05-08 | シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017092571A Pending JP2017158577A (ja) | 2011-02-01 | 2017-05-08 | シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130030040A1 (enExample) |
| EP (2) | EP3202425A1 (enExample) |
| JP (2) | JP2014506787A (enExample) |
| KR (2) | KR102257741B1 (enExample) |
| AU (2) | AU2012212162A1 (enExample) |
| CA (1) | CA2863578C (enExample) |
| IL (1) | IL227773B (enExample) |
| MX (1) | MX365095B (enExample) |
| WO (1) | WO2012106465A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140057856A1 (en) * | 2012-08-22 | 2014-02-27 | The Regents Of The Universtiy Of California | Compositions and Methods For Enhancing Sialic Acid Levels In Tissue |
| US20150322439A1 (en) * | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
| US20140256639A1 (en) * | 2013-02-14 | 2014-09-11 | The Regents Of The University Of California | Peptoid neutralizing agents |
| CN103088090B (zh) * | 2013-03-01 | 2014-06-04 | 南京工业大学 | 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用 |
| CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN116217729A (zh) | 2015-11-12 | 2023-06-06 | 思进公司 | 聚糖相互作用化合物及使用方法 |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| CN110913903B (zh) | 2017-03-03 | 2024-03-01 | 思进股份有限公司 | 聚糖相互作用化合物和使用方法 |
| CN108285886A (zh) * | 2018-01-30 | 2018-07-17 | 江南大学 | 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法 |
| US11865165B2 (en) | 2018-09-18 | 2024-01-09 | Daniel DARVISH | GNE as a therapeutic agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070173465A9 (en) | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
| AU2001236739A1 (en) * | 2000-02-08 | 2001-08-20 | Genentech Inc. | Improved sialylation of glycoproteins |
| WO2004071177A2 (en) * | 2003-02-11 | 2004-08-26 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Sialylation of glycoproteins in plants |
| WO2005030292A2 (en) * | 2003-09-26 | 2005-04-07 | The Trustees Of The University Of Pennsylvania | Methods, compositions and apparatus for delivering heterologous molecules to cells |
| WO2008001023A1 (en) | 2006-06-27 | 2008-01-03 | Gigabeam Corporation | Cellular communication system |
| JP5415283B2 (ja) * | 2007-02-07 | 2014-02-12 | グラダリス インク． | シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物 |
| CA2684534C (en) | 2007-04-17 | 2017-04-04 | National Research Council Of Canada | Constructs for enhancement of gene expression in muscle |
| US9018174B2 (en) * | 2008-05-28 | 2015-04-28 | Hibm Research Group, Inc. | Mouse model and treatment of hereditary inclusion body myopathy |
| AU2009291861A1 (en) | 2008-09-09 | 2010-03-18 | The Regents Of The University Of California | Elimination of a contaminating non-human sialic acid by metabolic competition |
| US9045759B2 (en) * | 2009-01-21 | 2015-06-02 | James Arthur Williams | DNA plasmids with improved copy number |
| CN102482674B (zh) * | 2010-02-08 | 2014-03-26 | 韩国科学技术院 | 制备具有高唾液酸含量的重组糖蛋白的方法 |
-
2012
- 2012-02-01 AU AU2012212162A patent/AU2012212162A1/en not_active Abandoned
- 2012-02-01 KR KR1020197026529A patent/KR102257741B1/ko active Active
- 2012-02-01 JP JP2013552609A patent/JP2014506787A/ja active Pending
- 2012-02-01 CA CA2863578A patent/CA2863578C/en active Active
- 2012-02-01 KR KR1020137023105A patent/KR20140034150A/ko not_active Ceased
- 2012-02-01 MX MX2013008948A patent/MX365095B/es active IP Right Grant
- 2012-02-01 WO PCT/US2012/023536 patent/WO2012106465A2/en not_active Ceased
- 2012-02-01 EP EP16002499.8A patent/EP3202425A1/en not_active Withdrawn
- 2012-02-01 EP EP12742231.9A patent/EP2670442A4/en not_active Withdrawn
- 2012-02-01 US US13/364,181 patent/US20130030040A1/en not_active Abandoned
-
2013
- 2013-08-01 IL IL227773A patent/IL227773B/en active IP Right Grant
-
2014
- 2014-05-22 US US14/285,602 patent/US10098969B2/en active Active - Reinstated
-
2017
- 2017-05-05 AU AU2017203027A patent/AU2017203027B2/en not_active Ceased
- 2017-05-08 JP JP2017092571A patent/JP2017158577A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506787A5 (enExample) | ||
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| CN102766204B (zh) | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| JP2016516016A5 (enExample) | ||
| JP2013534426A5 (enExample) | ||
| UA126960C2 (uk) | Похідна глюкагону | |
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| JP7511469B2 (ja) | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 | |
| EP4134084A3 (en) | Tissue-specifically expressed circular rna molecule and application thereof | |
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| MX2013008948A (es) | Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| RU2017124487A (ru) | НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ | |
| KR20230017804A (ko) | Rhfgf21 융합 단백질, rhfgf21 융합 단백질을 인코딩하는 폴리뉴클레오티드, rhfgf21 융합 단백질을 포함하는 조성물, 및 rhfgf21 융합 단백질의 용도 | |
| JP2022060514A (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 | |
| JP2020514305A5 (enExample) | ||
| JP5189985B2 (ja) | コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法 | |
| CN115996943A (zh) | 用于影响免疫信号传导和/或影响肠屏障功能和/或调节代谢状态的Amuc-1100多肽变体 | |
| CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
| JP2009507474A5 (enExample) | ||
| CN102108097A (zh) | 一种新型glp-1衍生物 | |
| JPWO2021148411A5 (enExample) | ||
| JP2014512369A5 (enExample) | ||
| CN100484957C (zh) | 胸腺素β4衍生物及其应用 |